	US 11,986,464 B2
	5HT3R antagonist for use in treating aneurysms and cardiovascular risk
Lisa Cassis, Nicholasville, KY (US); Sean Thatcher, Lexington, KY (US); Yasir Alsiraj, Lexington, KY (US); Mark Ensor, Lexington, KY (US); and Eric Blalock, Lexington, KY (US)
Assigned to University of Kentucky Research Foundation, Lexington, KY (US)
Filed by University of Kentucky Research Foundation, Lexington, KY (US)
Filed on May 2, 2022, as Appl. No. 17/734,571.
Claims priority of provisional application 63/182,161, filed on Apr. 30, 2021.
Prior Publication US 2022/0347161 A1, Nov. 3, 2022
Int. Cl. A61K 31/439 (2006.01); A61K 31/40 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/46 (2006.01); A61P 3/06 (2006.01); A61P 9/10 (2006.01)

CPC A61K 31/439 (2013.01) [A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/46 (2013.01); A61P 3/06 (2018.01); A61P 9/10 (2018.01)]

20 Claims

1. A method of treating or reducing risk of aneurysm, comprising: administering to a subject in need of such treatment or reduction of risk of aneurysm an effective amount of a 5HT₃R antagonist or pharmaceutically-acceptable salt thereof.